Literature DB >> 33496840

Photodynamic studies reveal rapid formation and appreciable turnover of tau inclusions.

Cara L Croft1,2,3,4, Marshall S Goodwin1,2,3, Daniel H Ryu1,2, Christian B Lessard1,2,3, Giancarlo Tejeda1,2, Marc Marrero1,2, Ava R Vause1,2, Giavanna Paterno1,2, Pedro E Cruz1,2,3, Jada Lewis1,2,3, Benoit I Giasson1,2,3, Todd E Golde5,6,7,8.   

Abstract

Accumulation of the tau protein in fibrillar intracellular aggregates is a defining feature of multiple neurodegenerative diseases collectively referred to as tauopathies. Despite intensive study of tau, there is limited information on the formation and clearance dynamics of tau inclusions. Using rAAV vectors to mediate expression of Dendra2-tagged human wild-type, P301L and pro-aggregant P301L/S320F tau proteins, with and without the addition of exogenous tau fibrillar seeds, we evaluated tau inclusion dynamics in organotypic brain slice culture (BSC) models using long-term optical pulse labeling methodology. Our studies reveal that tau inclusions typically form in 12-96 h in tauopathy BSC models. Unexpectedly, we demonstrate appreciable turnover of tau within inclusions with an average half-life of ~ 1 week when inclusions are newly formed. When BSCs with inclusions are aged in culture for extended periods, tau inclusions continue to turnover, but their half-lives increase to ~ 2 weeks and ~ 3 weeks after 1 and 2 months in culture, respectively. Individual tau inclusions can be long-lived structures that can persist for months in these BSC models and for even longer in the human brain. However, our data indicate that tau inclusions, are not 'tombstones', but dynamic structures with appreciable turnover. Understanding the cellular processes mediating this inclusion turnover may lead to new therapeutic strategies that could reverse pathological tau inclusion formation.

Entities:  

Keywords:  Brain slice culture; Microtubule-associated protein tau; Optical pulse labeling; Recombinant adeno-associated viruses; Tau inclusion turnover

Mesh:

Substances:

Year:  2021        PMID: 33496840      PMCID: PMC7882582          DOI: 10.1007/s00401-021-02264-9

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  56 in total

1.  Proteasomal degradation of tau protein.

Authors:  Della C David; Robert Layfield; Louise Serpell; Yolanda Narain; Michel Goedert; Maria Grazia Spillantini
Journal:  J Neurochem       Date:  2002-10       Impact factor: 5.372

2.  Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs.

Authors:  A B Rocher; J L Crimins; J M Amatrudo; M S Kinson; M A Todd-Brown; J Lewis; J I Luebke
Journal:  Exp Neurol       Date:  2009-08-07       Impact factor: 5.330

3.  Propagation of tau pathology in a model of early Alzheimer's disease.

Authors:  Alix de Calignon; Manuela Polydoro; Marc Suárez-Calvet; Christopher William; David H Adamowicz; Kathy J Kopeikina; Rose Pitstick; Naruhiko Sahara; Karen H Ashe; George A Carlson; Tara L Spires-Jones; Bradley T Hyman
Journal:  Neuron       Date:  2012-02-23       Impact factor: 17.173

4.  Microtubule-associated protein tau. A component of Alzheimer paired helical filaments.

Authors:  I Grundke-Iqbal; K Iqbal; M Quinlan; Y C Tung; M S Zaidi; H M Wisniewski
Journal:  J Biol Chem       Date:  1986-05-05       Impact factor: 5.157

5.  Tau suppression in a neurodegenerative mouse model improves memory function.

Authors:  K Santacruz; J Lewis; T Spires; J Paulson; L Kotilinek; M Ingelsson; A Guimaraes; M DeTure; M Ramsden; E McGowan; C Forster; M Yue; J Orne; C Janus; A Mariash; M Kuskowski; B Hyman; M Hutton; K H Ashe
Journal:  Science       Date:  2005-07-15       Impact factor: 47.728

Review 6.  Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs.

Authors:  Mark S Forman; John Q Trojanowski; Virginia M-Y Lee
Journal:  Nat Med       Date:  2004-10       Impact factor: 53.440

7.  Thinking laterally about neurodegenerative proteinopathies.

Authors:  Todd E Golde; David R Borchelt; Benoit I Giasson; Jada Lewis
Journal:  J Clin Invest       Date:  2013-05-01       Impact factor: 14.808

8.  Unique pathological tau conformers from Alzheimer's brains transmit tau pathology in nontransgenic mice.

Authors:  Jing L Guo; Sneha Narasimhan; Lakshmi Changolkar; Zhuohao He; Anna Stieber; Bin Zhang; Ronald J Gathagan; Michiyo Iba; Jennifer D McBride; John Q Trojanowski; Virginia M Y Lee
Journal:  J Exp Med       Date:  2016-10-17       Impact factor: 14.307

9.  rAAV-based brain slice culture models of Alzheimer's and Parkinson's disease inclusion pathologies.

Authors:  Cara L Croft; Pedro E Cruz; Daniel H Ryu; Carolina Ceballos-Diaz; Kevin H Strang; Brittany M Woody; Wen-Lang Lin; Michael Deture; Edgardo Rodríguez-Lebrón; Dennis W Dickson; Paramita Chakrabarty; Yona Levites; Benoit I Giasson; Todd E Golde
Journal:  J Exp Med       Date:  2019-02-15       Impact factor: 14.307

10.  Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau.

Authors:  Kevin H Strang; Marshall S Goodwin; Cara Riffe; Brenda D Moore; Paramita Chakrabarty; Yona Levites; Todd E Golde; Benoit I Giasson
Journal:  Acta Neuropathol Commun       Date:  2017-07-31       Impact factor: 7.801

View more
  8 in total

1.  Does Data-Independent Acquisition Data Contain Hidden Gems? A Case Study Related to Alzheimer's Disease.

Authors:  Evan E Hubbard; Lilian R Heil; Gennifer E Merrihew; Jasmeer P Chhatwal; Martin R Farlow; Catriona A McLean; Bernardino Ghetti; Kathy L Newell; Matthew P Frosch; Randall J Bateman; Eric B Larson; C Dirk Keene; Richard J Perrin; Thomas J Montine; Michael J MacCoss; Ryan R Julian
Journal:  J Proteome Res       Date:  2021-11-24       Impact factor: 4.466

2.  Tau isoforms are differentially expressed across the hippocampus in chronic traumatic encephalopathy and Alzheimer's disease.

Authors:  Jonathan D Cherry; Camille D Esnault; Zachary H Baucom; Yorghos Tripodis; Bertrand R Huber; Victor E Alvarez; Thor D Stein; Dennis W Dickson; Ann C McKee
Journal:  Acta Neuropathol Commun       Date:  2021-05-12       Impact factor: 7.578

Review 3.  Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers.

Authors:  Todd E Golde
Journal:  Neurotherapeutics       Date:  2022-02-28       Impact factor: 7.620

4.  Pathogenic tau recruits wild-type tau into brain inclusions and induces gut degeneration in transgenic SPAM mice.

Authors:  Yuxing Xia; Stefan Prokop; Brach M Bell; Kimberly-Marie M Gorion; Cara L Croft; Lith Nasif; Guilian Xu; Cara J Riffe; Alyssa N Manaois; Kevin H Strang; Stephan S Quintin; Giavanna Paterno; Malú Gámez Tansey; David R Borchelt; Todd E Golde; Benoit I Giasson
Journal:  Commun Biol       Date:  2022-05-12

5.  Parallel gold enhancement of quantum dots 565/655 for double-labelling correlative light and electron microscopy on human autopsied samples.

Authors:  Miho Uematsu; Kyohei Mikami; Ayako Nakamura; Ryosuke Takahashi; Takanori Yokota; Katsuiku Hirokawa; Toshiki Uchihara
Journal:  Sci Rep       Date:  2022-04-12       Impact factor: 4.379

6.  Cortical waste clearance in normal and restricted sleep with potential runaway tau buildup in Alzheimer's disease.

Authors:  Tahereh Tekieh; P A Robinson; Svetlana Postnova
Journal:  Sci Rep       Date:  2022-08-12       Impact factor: 4.996

7.  Tau inclusion turnover could be a target.

Authors:  Ian Fyfe
Journal:  Nat Rev Neurol       Date:  2021-03       Impact factor: 42.937

Review 8.  Tau Seeding Mouse Models with Patient Brain-Derived Aggregates.

Authors:  Aiko Robert; Michael Schöll; Thomas Vogels
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.